Medicenna Announces Results of Annual Meeting of Shareholders

Rhea-AI Summary

Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF) held its annual meeting of shareholders on September 26, 2024. All nominees listed in the management information circular were elected as directors. The voting results for each nominee were as follows:

• Dr. Fahar Merchant: 99.44% votes for
• Mr. Albert Beraldo: 99.77% votes for
• Dr. John (Jack) Geltosky: 99.26% votes for
• Ms. Karen Dawes: 99.41% votes for
• Dr. John H. Sampson: 77.42% votes for
• Mr. Karim Lalji: 99.73% votes for

Shareholders also voted for the appointment of MNP LLP as the Company's auditor. A total of 45.89% of the issued and outstanding common shares were represented at the meeting.

Positive

• High approval rates for most board nominees, with five out of six receiving over 99% votes in favor
• Successful appointment of MNP LLP as the company's auditor

Negative

• Relatively low shareholder participation with only 45.89% of issued and outstanding shares represented at the meeting
• Dr. John H. Sampson received significantly lower approval at 77.42% compared to other nominees

TORONTO and HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced the voting results from the Company’s annual meeting of shareholders held today, September 26, 2024 (the “Meeting”).

Medicenna is pleased to announce that all nominees listed in the management information circular dated August 14, 2024 (the “Circular”), were elected as directors. The results of the vote are detailed below:

	Nominee	Votes For		% of Votes For		Votes Against		% of Votes Against
	Dr. Fahar Merchant	26,237,107		99.44%		148,557		0.56%
	Mr. Albert Beraldo	26,325,950		99.77%		59,714		0.23%
	Dr. John (Jack) Geltosky	26,190,452		99.26%		195,212		0.74%
	Ms. Karen Dawes	26,228,732		99.41%		156,932		0.59%
	Dr. John H. Sampson	20,428,706		77.42%		5,956,958		22.58%
	Mr. Karim Lalji	26,314,082		99.73%		71,582		0.27%

Medicenna shareholders also voted for the appointment of MNP LLP as auditor of the Company.

A total of 45.89% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.

Please refer to the Circular available on SEDAR+ at www.sedarplus.ca for more information on the business transacted at the Meeting. A report on voting results will also be filed on SEDAR+.

About Medicenna Therapeutics

Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna’s early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Medicenna’s early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and the T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically “cold” tumors.

For more information, please visit www.medicenna.com, and follow us on Twitter and LinkedIn.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook or other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially”, “equivocally,” and similar expressions and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest annual information form and in other filings made by the Company with the applicable securities regulators from time to time in Canada.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.

This news releases contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.

Further Information & Investor/Media Contact:

Christina Cameron
Investor Relations, Medicenna Therapeutics
(647) 953-0673
ir@medicenna.com

FAQ

What were the voting results for Medicenna Therapeutics Corp's (MDNAF) 2024 annual meeting?

All nominees were elected as directors, with five out of six receiving over 99% approval. Dr. John H. Sampson received 77.42% approval. Shareholders also approved the appointment of MNP LLP as auditor.

How many shares were represented at Medicenna Therapeutics Corp's (MDNAF) 2024 annual meeting?

A total of 45.89% of the issued and outstanding common shares of Medicenna Therapeutics Corp were represented in person and by proxy at the annual meeting held on September 26, 2024.

Who received the highest percentage of votes for director at Medicenna Therapeutics Corp's (MDNAF) 2024 annual meeting?

Mr. Albert Beraldo received the highest percentage of votes for director with 99.77% of votes in favor at Medicenna Therapeutics Corp's 2024 annual meeting.